Hyderabad Stories
Hyderabad Stories
dr.reddy's

Dr Reddy’s

Pharmaceutical company

Company Overview

About Dr Reddy’s

Dr. Reddy’s Laboratories Limited was founded in 1984 and provides a complete range of pharmaceutical services. They manufacture medicines and drugs to supply affordable and innovative medicines. The company initially began as a supplier to Indian drug manufacturers, but soon started exporting their products to the world. Dr. Reddy is engaged in manufacturing and marketing active pharmaceutical ingredients and intermediates.

Founders & Leadership

People Behind Dr Reddy’s

Watch

Related video

3 on YouTube · opens in a new tab

STORIES & COVERAGE

Stories & Press Coverage

  1. Times of India

    Hyderabad-based Divi’s Labs second pharma company with Rs 1 lakh crore market capitalization

    City-based Divi’s Laboratories on Thursday became the second pharma player in the country, after Sun Pharma, to enter the elite league of companies with a market capitalization of Rs 1 lakh crore or more.

  2. Telangana Today

    Belgium forging ties with Hyderabad

    Belgium is strengthening its ties with Hyderabad, India’s largest life sciences hub, to help supply vaccines and drugs to global markets, particularly to the Europe region.

  3. Economic Times

    Stock market update: Nifty Pharma index jumps nearly 3%; Dr Reddy's Lab climbs 4%

    Nifty Pharma index was trading with losses at 11:48 AM (IST) on Monday. Shares of Dr.

  4. The Hindu

    Dr Reddy's Laboratories launches succinylcholine chloride injection in US

    Dr. Reddy’s Laboratories Ltd has launched Succinylcholine Chloride injection, a therapeutic equivalent generic version of Quelicin (Succinylcholine Chloride) injection, in the US market.

  5. Telangana Today

    Dr Reddy’s, RDIF receive approval to conduct clinical trial for Sputnik V vaccine

    Hyderabad-based pharmaceuticals company Dr Reddy’s Laboratories and Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, announced that they have received approval from the Drug Control General of India (DCGI) to conduct an adaptive phase 2/3 human clinical trial for Sputnik V vaccine in India.